spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

PredictImmune announce issuance of new patent in the US in support of commercialisation

US patent protects PredictImmune’s intellectual property relating to methods for predicting autoimmune disease risk

PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, today confirmed its latest patent grant in the US. The US patent is part of PredictImmune’s third family of intellectual property (IP) relating to methods for predicting autoimmune disease risk. This follows successful grants across the company’s first family of IP in the UK and Europe in October 2018 and Canada in January this year.

The focus of the US patent is on the biological mechanism of the test, which demonstrates whether a patient does or does not exhibit T-cell exhaustion. An ‘exhausted’ patients’ immune system isn’t able to respond effectively to infection, leaving them struggling to clear infections. However, the implication for patients with auto-immune disease is more positive – their exhausted CD8 cells are also less effective at mounting an auto-immune response, resulting in a milder form of such diseases.

PredictImmune’s entire portfolio of patents and other IP support its goal of enabling personalised medicine for a range of immune-mediated diseases. Licensed from Cambridge Enterprise, the US patent provides evidence to support the expansion of the PredictImmune product line beyond its first test for inflammatory bowel disease (IBD), into other related diseases and in turn, improve patient outcomes across a broader range of patients in the US as well as Europe.

Immune mediated diseases, such as IBD, are chronic and incurable with clinical courses that vary among individuals with the same disease. To date, these diseases have been treated with a ‘one size fits all’ approach, despite there being significant variation in disease course between patients with the same disease. This approach means that patients with a relatively mild form of the disease tend to be over treated, resulting in significant side effects, whilst those with a more aggressive form of the disease, can be under-medicated, resulting in frequent relapses or flare-ups, which result in long term damage and significant morbidity and mortality. PredictImmune’s tests, give clinicians the ability to determine how aggressive a patients’ disease is at the point of diagnosis, enabling them to make informed decisions about the treatment course most relevant for each individual patient.

Paul Kinnon, CEO, PredictImmune commented: “We are excited by the issuance of our US patent as it provides further support of the novelty and innovation underpinning the development of our prognostic tests in these devastating and chronic diseases and further enables our US commercial strategy. It allows us to build on the ground-breaking research carried out over the last 15 years by Prof Ken Smiths’ laboratory at the Department of Medicine at the University of Cambridge, and focus on developing ground-breaking products that will help deliver the benefits of a more personalised approach to treatment for patients with these debilitating and life-threatening diseases.” The US patent grant comes at a pertinent time for PredictImmune - PredictSURE IBD™, the company’s first product addressing IBD (both Crohn’s disease and ulcerative colitis) launches in the UK imminently and in the US later this year.
For information: www.predictimmune.com
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Turkish Cargo sponsored the carriage of historical artifacts from the Topkapı and Dolmabahçe Palaces to Japan

Turkish Cargo, the air cargo brand of Turkish Airlines that provides service to 124 countries, carried 186 historical artifacts, owned by Dolmabahçe and Topkapı Palaces, to Tokyo, the capital of Japan, as the sponsor carrier, in order to be displayed at the exhibition titled as "The Ottoman Empire and Tulip Culture" held as part of the events organized for 2019 which was declared as the "Year of Turkish Culture" across Japan.
More info >>


White Papers

Extractables and Leachables Testing: A Risk Based Approach

RSSL

Pharmaceutical products are in contact with many external components during both manufacture and usage and small amounts of chemicals may leach from these components with a potential health risk to the patient. Extractables and leachables (E&L) studies therefore play an important role in verifying the safety of a drug product over its lifetime. Regulatory organisations such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) are taking an increased interest in the interactions of various drug delivery devices, pharmaceutical product containers and medical devices with drug product and/or patient and this field is therefore growing in importance. Regulatory guidelines indicate that an extractables profile should be determined for all materials that contact the drug product. Once established, this profile can be used to determine whether any of these extractables are present as leachables within the product. If a leachable is detected, amounts can be determined using validated analytical methods, after which a biological risk can be established based on the exposure. This white paper will provide an overview of the processes used to determine extractables and leachables from plastics.
More info >>

Industry Events

LogiPharma 2019

9-11 April 2019, Montreux Music & Convention Centre

LogiPharma is the world’s leading pharma supply chain event. With over 950+ pharma supply chain leaders exclusively meeting in one place at one time, LogiPharma is THE meeting place to benchmark your business with the best pharma companies and shape the future of your industry.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement